Organization
AstraZeneca Plc
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
AstraZeneca Plc
... "no deal" contingency plans to avert problems in the supply of medicines. AstraZeneca, an Anglo-Swedish company, and Eisai, a Japanese one, have already started to ...
... specific barriers affecting 12 named drugs from the leading manufacturers including Novo Nordisk,AstraZeneca, Boehringer Ingelheim and Novartis. Top Takeaways - Turning negatives to positives: Physicians ...
... AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new ...
... is one of the best-selling drugs for the company that makes it, AstraZeneca. In 2016, the drug brought in over $2 billion in revenue, according ...
... At the ESMO Asia 2017 Congress in Singapore, 17-19 November 2017, AstraZeneca and MedImmune, its global biologics research and development arm, will share ground-breaking ...
... AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval ...
... AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved ...
... AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand ...
... he previously held positions in early oncology clinical development at Genzyme and AstraZeneca. About Deep-Primed(TM) Immune Cell TherapeuticsTorque's Deep-Priming platform is based on 10 years ...
... AstraZeneca today announced that the European Commission (EC) has approved a new indication ...
... 1. AstraZeneca sales fell as the British drugmaker faced generic competition for its cholesterol-lowering ...
... AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining ...
... ASTRAZENECA is betting on new lung cancer drugs and growth in the Chinese ...
... ASTRAZENECA tentatively upped its full-year core earnings guidance yesterday, as the pharmaceuticals giant ...
... head start in this setting with recent approvals for Keytruda; however, BMS, AstraZeneca, Roche and Merck Group/Pfizer still have much to play for. As fist-line ...
... (alectinib; Roche) Cyramza (ramucirumab; Eli Lilly) Gilotrif (afatinib; Boehringer Ingelheim) Iressa (gefitinib; AstraZeneca) Keytruda (pembrolizumab; Merck & Co.) Opdivo (nivolumab; Bristol-Myers Squibb) Portrazza (necitumumab; Eli ...
... hear from over 60 + expert speakers from companies such as Novartis, AstraZenecahttp://bit.ly/2iGqS7J Over four days attendees will be taking on the full supply chain ...
... LONDON (AP) - Anglo-Swedish drugmaker AstraZeneca says its net income and sales fell in the third quarter as ...
... cardiovascular, metabolic or respiratory medicines. And that’s what happened 58 minutes into AstraZeneca’s third-quarter earnings call. As they have in recent quarters, analyst queries focused ...
... Sanofi put up $805 million to license a preclinical multiple sclerosis drug. AstraZeneca revealed tezepelumab missed the primary endpoint in an atopic dermatitis trial. Boehringer ...
... AstraZeneca and Amgen’s tezepelumab has missed (PDF) the primary endpoint in a phase ...
... which occurred in 2013.The exclusive licensing agreement in 2016 between Ironwood and AstraZeneca worth $265m for the US rights to Zurampic(lesinurad) and the fixed-dose combination ...
... trial activity in the cervical cancer space is dominated by ongoing trials. AstraZeneca and Roche have the highest number of ongoing clinical trials for cervical ...
... AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining ...
... AstraZeneca as part of a respiratory alliance signed in May 2017, with AstraZeneca funding the cost of this study. Dosing of the first subject will ...
... and under-excretion of serum uric acid, in a single pill. Ironwood paid AstraZeneca a $ 15.0 million milestone upon the approval of DUZALLO during the ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤